Patents Examined by Jeffrey S. Parkin
  • Patent number: 11389527
    Abstract: Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: July 19, 2022
    Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of Health
    Inventor: Ma Luo
  • Patent number: 11370830
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 28, 2022
    Assignee: The Rockefeller University
    Inventors: Davide Robbiani, Michel Nussenzweig
  • Patent number: 11369674
    Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: June 28, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
  • Patent number: 11345726
    Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 31, 2022
    Assignee: VLP Theranentics. Inc.
    Inventors: Ryuji Ueno, Wataru Akahata
  • Patent number: 11344614
    Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner.
    Type: Grant
    Filed: September 29, 2018
    Date of Patent: May 31, 2022
    Assignee: Emergex Vaccines Holding Ltd.
    Inventor: Ramila Philip
  • Patent number: 11344615
    Abstract: Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 31, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Claire Y. H. Kinney
  • Patent number: 11338030
    Abstract: The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: May 24, 2022
    Assignee: Bavarian Nordic A/S
    Inventors: Ariane Volkmann, Robin Steigerwald, Hubertus Hochrein, Ulrike Dirmeier, Henning Lauterbach, Jürgen Hausmann
  • Patent number: 11325946
    Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: May 10, 2022
    Assignees: LABORATORIOS DEL DR. ESTEVE S.A., FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDE—CAIXA
    Inventors: Christian Brander, Beatriz Mothe Pujadas, Anuska Llano
  • Patent number: 11318196
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 3, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: 11319362
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 3, 2022
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, THERACLONE SCIENCES, INC.
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 11319351
    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 ß-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 3, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Alexander Riedel, Christian Scholz, Peter Muench, Gloria Tabares, Mario Gloeck, Silke Luebcke, Juliane Benz
  • Patent number: 11312750
    Abstract: The disclosure concerns a polypeptide suitable for detecting antibodies against Zika virus in an isolated biological sample having a Zika virus NS1 wing domain specific amino acid sequence and variants thereof, wherein no further Zika virus specific amino acid sequences are present in the polypeptide. This polypeptide does not immunologically cross-react with antibodies raised against structurally related antigens from tick-borne encephalitis virus, Dengue virus 1-4, West Nile virus, yellow fever virus or Japanese encephalitis virus, but immunologically reacts with antibodies raised against full length Zika virus NS1 antigen. Also disclosed is a method of producing a soluble and immunoreactive Zika virus NS1 polypeptide as well as methods and kits for detecting antibodies specific for Zika virus in an isolated sample.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Elke Faatz, Mario Gloeck, Peter Muench, Alexander Riedel, Christian Scholz, Gloria Tabares
  • Patent number: 11286295
    Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: March 29, 2022
    Assignee: SANOFI
    Inventors: Kara Carter, Cendrine Lemoine, Marie Mandron, Sunghae Park, Huawei Qiu, Jonathan Rothblatt
  • Patent number: 11267873
    Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 8, 2022
    Assignees: Massachusetts Institute of Technology, National University of Singapore
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Kuan Rong Chan, Satoru Watanabe, Subhash G. Vasudevan, Eng Eong Ooi
  • Patent number: 11261231
    Abstract: The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: March 1, 2022
    Assignees: Altor BioScience, LLC., The Regents of the University of Califoria
    Inventors: Richard B. Jones, Mario Ostrowski, Douglas F. Nixon, Lishomwa C. Ndhlovu, James Rini
  • Patent number: 11235055
    Abstract: Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 1, 2022
    Assignees: Triad National Security, LLC, Isis Innovation Limited
    Inventors: Bette T. M. Korber, Tomas Hanke, Andrew McMichael
  • Patent number: 11237174
    Abstract: The disclosure relates to a virus-like particle in which a protein complex is entrapped, ensuring the formation of the protein complex under physiological conditions, while protecting the protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of protein complexes.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: February 1, 2022
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Sven Eyckerman
  • Patent number: 11235056
    Abstract: Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Xuejun Chen, Jeffrey Boyington, Hongying Duan Holdsworth, Cheng Cheng, John R. Mascola
  • Patent number: 11236134
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: February 1, 2022
    Assignee: The Scripps Research Institute
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Patent number: 11237166
    Abstract: The present invention relates to a method for detecting and/or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence and/or amount of antibodies binding to a) a peptide consisting of the amino acid sequence AIVCTRPNNNTRKSIRIGPGQVFYT (SEQ. ID No. 1), or b) a homolog having at least 70% identity with a peptide of a), or c) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues in said sample.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: February 1, 2022
    Assignee: Viravaxx AG
    Inventors: Rudolf Valenta, Daniela Gallerano, Elopy N. Sibanda